It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available on the U.S. health regulator's website on ...

Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Nearly one-third of those patients were paying $35 or far more per month in 2019, according to the latest available data from ...

Eli Lilly fell short of Wall Street sales estimates for its weight-loss and diabetes drugs on Wednesday, hit by a decrease in ...

The updated AAP clinical guidelines on obesity treatment recommend offering the full spectrum of care upon initial obesity ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...